Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-7,007
Closed -$247K 687
2023
Q3
$247K Buy
+7,007
New +$267K 0.02% 538
2023
Q2
Sell
-10,976
Closed -$465K 782
2023
Q1
$465K Hold
10,976
0.02% 435
2022
Q4
$465K Sell
10,976
-2,900
-21% -$119K 0.02% 435
2022
Q3
$446K Buy
13,876
+2,773
+25% +$97.4K 0.02% 430
2022
Q2
$361K Sell
11,103
-18,984
-63% -$615K 0.01% 569
2022
Q1
$1.09M Buy
30,087
+2,580
+9% +$88.5K 0.04% 312
2021
Q4
$1.09M Buy
27,507
+716
+3% +$29.9K 0.03% 345
2021
Q3
$1.17M Sell
26,791
-1,855
-6% -$83.3K 0.04% 313
2021
Q2
$1.17M Sell
28,646
-176
-0.6% -$6.79K 0.04% 301
2021
Q1
$946K Buy
28,822
+636
+2% +$23.9K 0.04% 308
2020
Q4
$1.15M Buy
28,186
+204
+0.7% +$7.63K 0.05% 241
2020
Q3
$1.02M Sell
27,982
-4,010
-13% -$145K 0.05% 232
2020
Q2
$1.08M Sell
31,992
-6,284
-16% -$171K 0.06% 222
2020
Q1
$811K Buy
38,276
+3,162
+9% +$70.5K 0.05% 225
2019
Q4
$784K Sell
35,114
-626
-2% -$13.7K 0.04% 265
2019
Q3
$724K Buy
+35,740
New +$704K 0.05% 280

Other funds holding GMAB

FDx Advisors's GMAB Position: Q4 2023 in Review

FDx Advisors sold out of Genmab (GMAB) in Q4 2023, closing a stake of 7,007 shares — an estimated $247K sold.

FDx Advisors first reported a position in GMAB in Q3 2019 and held it in 16 quarters. The position peaked at $1.17M in Q3 2021. 225 funds tracked by Wall St. Rank hold GMAB as of Q4 2023.

  • FDx Advisors reported no remaining Genmab position as of Q4 2023 after selling out during the quarter.
  • FDx Advisors sold 7,007 Genmab shares in Q4 2023, an estimated $247K.
  • FDx Advisors first reported a position in Genmab in Q3 2019 and held it in 16 quarters.
  • FDx Advisors's Genmab position peaked at $1.17M in Q3 2021.
  • 225 funds tracked by Wall St. Rank held Genmab as of Q4 2023.

Based on FDx Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.